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Abstract
Background: Cisplatin is a high-potency anticancer agent; however, it causes significant adverse drug reactions
(ADRs). Potential pharmacokinetic markers must be studied to predict or prevent cisplatin-induced ADRs and
achieve better prognosis. This study was designed to investigate the relationship between ADRs and kinetics of
cisplatin excretion in the urine of patients undergoing high-dose cisplatin chemotherapy and radiotherapy for head
and neck cancer.
Methods: Outpatients with head and neck cancer received a first cycle of high-dose cisplatin chemotherapy (80–
100 mg/m2) concurrent to radiotherapy. ADRs (haematological, renal, and gastrointestinal reactions) were classified
based on severity by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE, version 4,
grade 0–4). The kinetics of cisplatin excretion in urine was evaluated by high-performance liquid chromatography over
three time periods: 0–12, 12–24, and 24–48 h after the administration of cisplatin. Spearman Correlation test and
regression analysis were performed to assess the relationship between ADRs and cisplatin excretion in the urine.
Results: In total, 59 patients with a mean age of 55.6 ± 9.4 years were analysed; most patients were male (86.4%), white
(79.7%), and with pharyngeal tumours in advanced stages (66.1%). The most frequently observed ADRs were anaemia
(81.4%), lymphopenia (78%), and nausea (64.4%); mostly grades 1 and 2 of toxicity. The mean cisplatin excretion was
70.3 ± 64.4, 7.3 ± 6.3, and 5 ± 4 μg/mg creatinine at 0–12, 12–24, and 24–48 h, respectively. Statistical analysis showed
that the amount of cisplatin excreted did not influence the severity of ADRs.
Conclusions: The most frequent ADRs were anaemia, lymphopenia, and nausea. Grades 1 and 2 were the severities for
most ADRs. The period over which the highest cisplatin excretion observed was 0–12 h after chemotherapy, and
cisplatin excretion could not predict toxicity.
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Background
Head and neck squamous cell carcinomas (HNSCC) are
malignant tumours located in the upper aerodigestive
tract, and the most commonly affected sites are the oral
cavity, pharynx, and larynx [1]. The best treatment for ad-
vanced HNSCC when surgery is contraindicated includes
chemoradiation, i.e. chemotherapy with a platinum-based
drug along with conventional radiotherapy. Chemoradia-
tion increases patient survival of 5 years by 8% and lowers
mortality risk by 19% compared with radiotherapy alone
[2]. Available and validated literature recommends the
treatment based on high-dose cisplatin chemotherapy
(100 mg/m2) every 3 weeks along with conventional radio-
therapy [3, 4]. However, chemoradiation has a high risk
for severe toxicity.
The most commonly used platinum derivative is
cisplatin. It is a complex containing a central atom of
platinum surrounded by two chlorine atoms and two
ammonia groups. Its cytotoxic action is analogous to
that of alkylating agents. When entering the cell, the
chloride ion dissociates, leaving a reactive complex that
reacts with water and then interacts with the DNA by
forming covalent bonds, preferably at the N7 position of
adenine and guanine. The reaction at two different DNA
sites produces intrachain (>90%) or interchain (<5%)
bonds. These platinum-DNA complexes can inhibit
DNA synthesis and consequently its transcription, which
leads to the induction of apoptosis in tumour cells [5].
Furthermore, cisplatin binds to mitochondrial DNA that
inhibits adenosine triphosphate (ATP) production, re-
duces ATPase activity, changes intracellular calcium
content, and decreases the rate of cellular respiration,
which results in the production of reactive oxygen spe-
cies and cellular lipid peroxidation [6].
After intravenous administration, 90% of the cisplatin
binds with plasma proteins such as albumin, gammaglo-
bulin, and transferrin [7] and is distributed to the tis-
sues, particularly the kidney, liver, and prostate [8]. The
formation of conjugates between glutathione and cis-
platin, through the action of glutathione-S-transferase, is
an important step in the inactivation and elimination of
cisplatin [9, 10]. Cisplatin is primarily excreted by the
kidneys [11]. In a study of the administration of radio-
active cisplatin, urinary elimination was incomplete with
25–45% of the radioactivity decay in the first 5 days.
Furthermore, the level of radioactive decay occurred in a
biphasic manner: half-life varied from 25 to 49 min and
from 58 to 73 h in the initial and terminal phases,
respectively [7].
As described, cisplatin is a high-potency anticancer
agent with favourable pharmacokinetics. However, it has
been noted that, similar to other antineoplastic agents, it
causes significant adverse drug reactions (ADRs) such as
myelosuppression, emesis, and nephrotoxicity. It is
necessary to study potential pharmacokinetic and/or
genetic markers to predict or prevent ADRs and achieve
a better clinical outcome. Pharmacokinetic studies are
usually performed to determine the drug concentration
in the blood; however, there is a good correlation be-
tween the cisplatin concentration in the blood and urine,
indicating that both methods can be used in the phar-
macokinetic studies of cisplatin [12]. Regarding the
intracellular concentration of cisplatin, a correlation be-
tween cisplatin concentration in the plasma and forma-
tion of cisplatin-DNA adducts in leukocytes of cancer
patients is controversial [13, 14].
Studies designed to investigate the association between
cisplatin excretion in urine and its ADRs are scarce.
Therefore, the current study aimed to investigate the re-
lationship between ADRs and the kinetics of cisplatin
excretion in the urine of patients undergoing high-dose
chemotherapy and radiotherapy for head and neck
cancers.
Methods
Study design
This was a prospective study, with consecutive sampling
performed from May 2011 to January 2013, conducted
at the Clinical Oncology department of a teaching hos-
pital in São Paulo, Brazil. The Research Ethics Commit-
tee of the institution approved this study and all patients
signed a consent form authorising the use of their data
(number 274/2011, CAAE: 0218.0.146.000-11).
Eligibility criteria
The study included patients with HNSCC (primary
tumour) and on high-dose cisplatin chemotherapy (80–
100 mg/m2) with concurrent radiotherapy. Patients who
had undergone tumour treatment in the past (surgery,
chemotherapy, or radiotherapy), those with severe psy-
chiatric problem, those who used nephrotoxic drugs, or
those who refused to participate were excluded.
Treatment protocols
Chemotherapy comprised three cycles of chemotherapy
with high-dose (80–100 mg/m2) cisplatin on days 1, 22,
and 43. In this study, we investigated only the first cycle
of chemotherapy. On each day of chemotherapy, the pa-
tients received vigorous hydration (3 L of saline solution
0.9%), diuretics (125 mL of mannitol 20%), electrolytes
(20 mL of potassium chloride 19.1% and 10 mL of mag-
nesium sulphate 10%), and prophylaxis of acute emesis
(20 mg of dexamethasone plus 24 mg of ondansetron).
For the treatment and prevention of delayed emesis, the
patients received 10 mg metoclopramide every 6 h and
8 mg dexamethasone every 12 h for three consecutive
days after the chemotherapy sessions.
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Concomitant with the three cycles of chemotherapy, the
patients received a total dose of 70 Gy of radiation therapy
divided into 35 daily applications of 2 Gy administered for
5 days per week for 7 weeks. Radiation was performed
using cobalt-60 (Alcyon II, GE, France) and a linear accel-
erator (6 MV) (Varian Medical Systems, CA, USA).
Demographic and clinical data
Data about patient characteristics were obtained from
medical records and interviews with patients, including
information about age, gender, race, Karnofsky Perform-
ance Status (KPS), smoking and drinking categories
based on the studies by Jindal et al. [15] and Whitcomb
et al. [16], and on the site and stage of tumour [17].
Adverse drug reactions
ADRs investigated were haematological (anaemia,
leukopenia, neutropenia, lymphopenia and thrombocy
topenia), renal (change in serum creatinine and creatin-
ine clearance) and gastrointestinal reactions (nausea,
vomiting and diarrhoea).
The blood samples of all the patients were collected
before (at least 1 week) and after chemotherapy (15–20
days later) for the evaluation of haematological and renal
reactions. The values of haemoglobin, leukocytes, neu-
trophils, lymphocytes, platelets and serum creatinine
were obtained. Creatinine clearance was estimated using
the Cockroft–Gault formula based on the weight, age
and serum creatinine levels of the patient. The values
were also used for the classification of ADRs in relation
to severity, according to the National Cancer Institute
Common Terminology Criteria for Adverse Events
(CTCAE, version 4) [18]. Anaemia is common before
the beginning of treatment in cancer patients; thus, for
the subjects whose haemoglobin levels were below nor-
mal before treatment, the toxicity after treatment was
classified as grade 1 when the reduction of haemoglobin
was ≥1 g/dL from the baseline, considering significant
variation. When the baseline values of lymphocytes and
creatinine clearance were not normal, toxicity was con-
sidered when the reduction was ≥10% from the baseline,
considering the biological variation [19, 20] and 1% of
balance variation.
The severity of gastrointestinal reactions was also clas-
sified according to CTCAE [18], considering the higher
grade the symptom reached on Day 1 (first 24 h after
chemotherapy–acute phase) to Day 5 (24–120 h after
chemotherapy–delayed phase). The number of patients
with reactions on each day of occurrence (Day 1–5) was
evaluated.
Kinetics of cisplatin excretion in urine
The 24-h urine samples of the patients were collected in
urine collection bottles (2.5 L polypropylene bottle) by
voluntary urination during three distinct periods (first
period: 0–12 h, the second period: 12–24 h and last
period: 24–48 h) after the administration of cisplatin.
Following the collection, the sample was homogenised
and an aliquot of 45 mL was stored in falcon tube at
−80 °C until analysis [21, 22].
For cisplatin urine detection, the previously described
procedure was followed [23] with some modifications: In
9 mL of urine, 90 μL of nickel chloride (300 μg/mL) was
added (Merck, Darmstadt, Germany) as internal stand-
ard and 1 mL of diethyldithiocarbamate (DDTC 10% in
0.1 M NaOH) (Sigma-Aldrich, India) was added for deri-
vatizing. The sample was homogenised and left at 25 °C
for 1 h. Thereafter, 1 mL of chloroform was added
(Merck, Darmstadt, Germany) in each tube. The tubes
were centrifuged for 10 min at 3500 rpm. After centrifu-
gation, the tubes were gently homogenised and re-
centrifuged at 3500 rpm for 10 min. Following centrifu-
gation, the supernatant was discarded and the chloro-
form phase was transferred into a vial for HPLC and
subsequent analysis.
The analysis was performed using an HPLC Separation
Module system (Waters 2695, USA) with dual absorb-
ance detector (UV-visible detector, wavelength 254 nm)
(Waters 2487, USA) and a Hypersil ODS C18 column
(150 mm × 4 mm and 4 μm of particle size, Thermo,
USA). The HPLC conditions and mobile phase used
were according to a method described by Lopez-Flores
et al. [24]. The limit of detection was 0.15 μg/mL, the
limit of quantification was 0.45 μg/mL, the limit of lin-
earity was 150 μg/mL, and the variation coefficient was
3.40% for the HPLC method.
To normalise the cisplatin values quantified in the
urine, urinary creatinine level was determined using a
colorimetric/kinetic method (modified Jaffe reaction;
Creatinine Laborclin kit®, Paraná, Brazil). Urine was pre-
diluted (1:50) and the kit was used to determine urinary
creatinine.
Statistical analysis
Statistical analysis was performed using the Statistics
Program for Social Sciences for Windows (SPSS 16.0,
SPSS Inc., Chicago, IL, USA) and Statistical Analysis
System for Windows (SAS 9.4. SAS Institute Inc., 2002–
2008, Cary, NC, USA). The significance level for all ana-
lyses was 5% (p < 0.05). Continuous and categorical data
were described as mean and percentage, respectively.
Wilcoxon test (paired samples) and ANOVA with
repeated measures were used to analyse changes
between assessments (different times). The Spearman
Correlation test was used to check the linear correlation
between the kinetics of urinary excretion of cisplatin and
severity of ADRs and also between ADRs. For correla-
tions that were statistically significant (p < 0.05), we
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considered only correlation coefficient (R) ≥ 0.5 and R ≤
−0.5. We also used univariate linear and logistic regres-
sion analyses to check the association between the kinet-
ics of urinary cisplatin excretion and severity of ADRs.
Results
Of the recruited 95 patients, 36 patients were withdrawn
from the study before initiation of the treatment, mainly
due to change in the chemotherapy protocol (n = 18)
and death (n = 7), and 59 patients were a part of the
study. Demographics and clinical data of the patients are
presented in Table 1. The mean age of the patients was
55.6 ± 9.4 years. The patients received a mean dose of
153.6 ± 29.2 mg of cisplatin in the first chemotherapy
cycle.
Haematological parameters and renal function were
analysed for evaluating ADRs. The values of baseline
and after the first chemotherapy cycle are presented in
Table 2. After chemotherapy with cisplatin, all the pa-
rameters changed significantly. However, the mean
values for haemoglobin, lymphocytes, and creatinine
clearance were below normal.
The ADRs listed by patients were also studied in rela-
tion to its severity and classified as grade 0–4 as shown
in Table 3. The most frequent ADRs after the first
chemotherapy cycle with high-dose cisplatin were an-
aemia, lymphopenia, and nausea. Moreover, most of the
ADRs were grades 1 and 2.
Frequencies of nausea, vomiting, and diarrhoea were
also studied as a function of the days of occurrence: nau-
sea, day 1: n = 17 (28.8%), day 2: n = 28 (44.1%), day 3: n
= 30 (50.8%), day 4: n = 26 (44.1%), day 5: n = 26 (44.1%);
vomiting, day 1: n = 8 (13.6%), day 2: n = 17 (28.8%), day
3: n = 20 (33.9%), day 4: n = 16 (27.1%), day 5: n = 14
(23.7%); diarrhoea, day 1: n = 3 (5.1%), day 2: n = 4
(6.8%), day 3: n = 2 (3.4%), day 4: n = 1 (1.7%), day 5: n =
3 (5.1%). Nausea and vomiting were more frequent in
Table 1 Demographics and clinical data of study patients (N= 59)
Demographics and clinical characteristics N (%)
Gender
Men 51 (86.4)
Women 8 (13.6)
Race
White 47 (79.7)
Non-white 12 (20.3)
Smoking category
Non-smokers 03 (5.3)
Light smokers 0 (0.0)
Moderate smokers 07 (12.3)
Heavy smokers 47 (82.4)
Not evaluated 02 (3.4)
Drinking category
Abstainers 08 (14.8)
Light drinkers 03 (5.5)
Moderate drinkers 08 (14.8)
Heavy drinkers 20 (37.1)
Very heavy drinkers 15 (27.8)
Not evaluated 05 (8.5)
KPS
100 16 (27.1)
90 19 (32.2)
80 11 (18.7)
70 13 (22.0)
Tumour site
Pharynx 39 (66.1)
Larynx 14 (23.7)
Oral cavity 6 (10.2)
T Stage
T1 4 (6.8)
T2 10 (16.9)
T3 19 (32.2)
T4 26 (44.1)
N Stage
N0 12 (20.4)
N1 18 (30.5)
N2 19 (32.2)
N3 10 (46.9)
Stage
I 1 (1.7)
II 2 (3.4)
Table 1 Demographics and clinical data of study patients (N= 59)
(Continued)
III 16 (27.1)
IV 40 (67.8)
KPS Karnofsky Performance Status, N absolute number, SD standard deviation.
No patient had distant metastases
Smoking category was classified based on the study by Jindal et al. [15]. Non-
smokers were patients that denied having ever smoked; light, moderate and
heavy smokers were smokers and exsmokers, and they were classified according
to the smoking index (SI), which was the product of the average number of
cigarettes smoked per day and the duration of smoking in years; light (SI = 1 –
100), moderate (SI = 101 – 300) and heavy (SI ≥ 301) smokers. Drinking category
based on the study by Whitcomb et al. [16]. Average weekly alcohol intake during
the maximum lifetime drinking period (drinks/week): abstainers, no alcohol use
or <20 drinks in lifetime; light drinkers, ≤3 drinks/week; moderate drinkers, 4–7
drinks/week for females and 4–14 drinks/week for males; heavy drinkers, 8–34
drinks/week for females and 15–34 drinks/week for males; very heavy drinkers,
≥35 drinks/week
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the delayed phase (mainly day 2 and 3), but diarrhoea
did not have any such difference.
The kinetics of urinary excretion of cisplatin/urine cre-
atinine was analysed over three different periods (0–
12 h, 12–24 h and 24–48 h) (Fig. 1). It was observed that
patients excreted a significantly higher amount of cis-
platin in the first 12 h after chemotherapy.
As expected, significant correlations [severity by grade
and number variations (range)] were observed between
related ADRs: leukopenia and neutropenia (grade, R =
0.739, p < 0.001; range, R = 0.894, p < 0.001); increased
creatinine and reduced creatinine clearance (grade, R =
0.636, p < 0.001; range, R = 0.893, p < 0.001) and nausea
and vomiting (grade, R = 0.619, p < 0.001).
ADRs [severity by grade and number variations
(range)] had no significant correlation with the elim-
ination of cisplatin in the urine (0–12 h, 12–24 h and
24–48 h) (Table 4). When the univariate linear and
logistic regression analyses were performed to evalu-
ate the same relationship, no significant result was
obtained (Table 4).
Discussion
In the present study, we attempted to elucidate the rela-
tionship between ADRs and cisplatin excretion in the
urine of patients undergoing a high-dose of cisplatin
chemotherapy and radiotherapy for head and neck can-
cer, an issue that has not been demonstrated in literature
yet. The pattern of ADRs and excretion of urinary
cisplatin was studied along with the days of occurrence
of gastrointestinal ADRs.
The mean concentration of haemoglobin in the patients’
blood before treatment was below the reference value for
men (14 g/dL). There is a relation between haematological
abnormalities and malignancies, including anaemia, which
may be present in 3.3–29.2% of patients with solid tu-
mours before treatment [25]. After the first chemotherapy
cycle, there was a significant reduction in the mean value
of haemoglobin and 81.4% of patients had anaemia. This
is in agreement with the results of a study by de Castro et
al. [26], in which 73% of patients treated with three cis-
platin cycles and radiotherapy had anaemia (50% grades 1
and 2; 23% grades 3 and 4); 47% of the patients required
Table 2 Haematological parameters and renal function before and after first chemotherapy cycle with high-dose cisplatin
Parameters Reference valuesa Mean ± SD p valueb
Baseline After 1st cycle
Haematological
Haemoglobin (g/L) 14–18 (men); 12–16 (women) 12.5 ± 1.7 10.7 ± 1.8 <0.0001
Leukocytes (×103/mm3) 4.0–10.0 9.9 ± 3.6 4.9 ± 2.4 <0.0001
Neutrophils (×103/mm3) 2.0–8.0 6.5 ± 2.7 3.1 ± 2.0 <0.0001
Lymphocytes (×103/mm3) 1.0–4.0 2.0 ± 0.7 0.7 ± 0.4 <0.0001
Platelets (×103/mm3) 150.0–400.0 332.6 ± 144.4 248.1 ± 105.1 <0.0001
Renal
Creatinine (mg/dL) <1.20 (men); <0.90 (women) 0.8 ± 0.2 1.0 ± 0.4 <0.0001
Creatinine clearance (mL/min) >90.0 84.0 ± 25.2 69.3 ± 26.2 <0.0001
aReference values of the studied institution. bComparison of the parameters before and after (variation) the 1st cycle (Wilcoxon test – paired samples). SD
standard deviation
Table 3 Frequency and severity of adverse drug reactions among study patients
Grade - N (%)
ADRs 1 2 3 4 Patients with ADRs
Haematological Anaemia 29 (49.2) 16 (27.1) 3 (5.1) 0 (0.0) 48 (81.4)
Leukopenia 12 (20.3) 9 (15.3) 1 (1.7) 2 (3.4) 24 (40.7)
Neutropenia 7 (11.8) 4 (6.8) 4 (6.8) 2 (3.4) 17 (28.8)
Lymphopenia 8 (13.6) 23 (39.0) 13 (22.0) 2 (3.4) 46 (78.0)
Thrombocytopenia 11 (18.6) 0 (0.0) 0 (0.0) 1 (1.7) 12 (20.3)
Renal Increase in serum creatinine 11 (19.0) 5 (8.6) 0 (0.0) 0 (0.0) 17 (27.6)
Reduction in creatinine clearance 14 (24.6) 20 (35.1) 2 (3.5) 0 (0.0) 36 (63.2)
Gastrointestinal Nausea 13 (22.0) 18 (30.5) 7 (11.9) - 38 (64.4)
Vomiting 11 (18.6) 9 (15.3) 8 (13.6) 0 (0.0) 28 (47.5)
Diarrhoea 5 (8.5) 2 (3.4) 1 (1.7) 0 (0.0) 8 (13.6)
ADRs Adverse Drug Reactions, N absolute number of patients
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red blood cell transfusion to maintain haemoglobin levels
above 10 g/dL during treatment.
Some patients had leukocyte, neutrophil and platelet
counts above the reference values before treatment, al-
though the average was within the normal range. In
Chinese patients with solid tumours, thrombocytosis
and leukocytosis before treatment were present in 4–
25.6% and 2.1–9.7%, respectively; these percentages are
higher in the occident [25]. As observed in oncology pa-
tients, cancer can cause chronic neutrophilia [27]. After
the first cycle of chemotherapy, there was a significant
reduction in these parameters as well as lymphocytes.
These changes are expected due to the myelotoxic
effects of cisplatin on the bone marrow [28]. Similar to
our results, the study by de Castro et al. [26], reported
that 63% of patients had lymphopenia, 32% neutropenia,
29% leukopenia and 13% thrombocytopenia. However,
there was a higher frequency of leukopenia, lymphopenia
and thrombocytopenia and lower frequency of neutro-
penia in our cohort.
The severity (grade) and numeric value of haemoglo-
bin levels did not correlate with leukocytes and platelets,
and the same was observed for neutrophils and lympho-
cytes. As previously mentioned, the main mechanism for
reducing these parameters by cisplatin is bone marrow
aplasia; however, these results suggest that the response
to aplasia could vary with the cell line.
In the present study, we observed a significant increase
in serum creatinine after treatment, which characterises
the acute nephrotoxicity caused by cisplatin. Arunkumar
et al. [29] also evaluated the effect of this antineoplastic
drug (40–50 mg/m2 weekly for 5 cycles) on serum cre-
atinine levels in patients with HNSCC. They observed
an increase (46.6%) in serum creatinine levels after treat-
ment (pretreatment serum creatinine: 0.73 ± 0.08 mg/dL,
serum creatinine after treatment: 1.07 ± 0.19 mg/dL; p <
0.05). In the current study, an increase of 25% in the mean
serum creatinine was observed.
The increase in creatinine was only classified as grade 1
and 2; a more severe increase in creatinine (grade 3 and 4)
was not observed in our study, probably due to the vigor-
ous hydration and administration of mannitol during the
course of chemotherapy. The study by de Castro et al.
[26] also reported increased creatinine in patients with
grade 1 and 2 (27%), similar to our study (27.6%). The in-
cidence is consistent with the literature; 20–41% [30] ex-
posed to cisplatin may develop kidney dysfunction.
In comparison with other chemotherapy drugs as well
as among platinum compounds, cisplatin is the strongest
emesis-inducing antineoplastic drug [31]. In this study, a
high prevalence of nausea and vomiting was observed;
nausea was the third major ADR, and vomiting was the
sixth most frequent ADR. Other studies also found nau-
sea and vomiting among the main ADRs in patients
treated with cisplatin: 60% and 67% [26], 54.9% and
41.2% [32] and 43% (nausea/vomiting) [33]. Moreover,
as observed by de Castro et al., most subjects had these
ADRs in grade 1 and 2 [26].
Nausea and vomiting were more frequent in the de-
layed phase, particularly on day 3 in our population. Kris
Fig 1 Kinetics of cisplatin excretion in urine.
a: Statistically significant compared with results for 12–24 h (ANOVA with repeated measures, p < 0.0001). b: Statistically significant compared with
results for 24–48 h (ANOVA with repeated measures, p < 0.0001). c: Statistically significant compared to period 0–12 h (ANOVA with repeated
measures, p < 0.0001). N = 53 (these analyses could not be done for 6 patients as urine was not collected or collected wrongly). Excreted cisplatin
over 0–48 h (sum of three periods) = 82.5 ± 66.5 μg of cisplatin/mg of creatinine
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et al. [34] analysed subjects treated with cisplatin and re-
ported delayed emesis (mostly days 2 and 3) in most of
them compared with the acute phase. Emesis is less fre-
quent in the first 24 h, which also confirms the findings
of Cohen et al. [35] who evaluated 151 cancer patients.
The urinary excretion profile of cisplatin is consistent
with the findings in literature. Litterest et al. [36, 37]
showed that cisplatin essentially undergoes renal excre-
tion and approximately 50% of the drug appears in the
urine within 24 h. Later, Gullo et al. [38] showed that
26.6–50% of cisplatin administered is excreted in the
urine in 48 h. Siddik et al. [39] found that 52% of cis-
platin is excreted in the urine within 3 days following its
administration, although most of it is excreted on day 1.
Only Gullo et al. conducted a pharmacokinetics study
on cisplatin in humans [38]. Pharmacokinetic studies de-
termined the plasma concentration of cisplatin per mL
of blood at various times during and after infusion. It
was observed that the dose administered is practically
related in time 0 after infusion with the total dose ad-
ministered [40–42]. Our study was not aimed to
determine the kinetics of cisplatin in the blood but to
compare the results with those of the studies cited, con-
sidering that 100% of the dose in the blood is the total
administered; the average cisplatin administered was
153.6 ± 29.2 mg, the average blood volume in adults is
4.4 L [43] (therefore, cisplatin blood concentration was
0.035 mg/mL), and the average values of cisplatin
excreted in urine in the first 12 h, 12–24 h and 24–48 h
were 42%, 9.4, and 9% of dose administered, which is
similar to previous studies.
There was no relationship between urinary excretion
of cisplatin and its ADRs. It appears that the severity of
ADRs is not linked to cisplatin clearance. The most ob-
vious result to be expected is that less drug elimination
predicts greater toxicity; however, this was not observed
in the study. It would be ideal to monitor serum cis-
platin; however, this is hampered by the need for blood
collection several times from patients who are physically
weak and anaemic.
Although no correlation was found between urinary
excretion and ADRs, the study results suggest the need
Table 4 Relationship between ADRs and cisplatin excretion in urine
Cisplatin excretion
0–12 h 12–24 h 24–48 h
SCT (R/p value) ULiR (p value) SCT (R/p value) ULiR (p value) SCT (R/p value) ULiR (p value)
Number variation (range)
Haemoglobin 0.000/1.000 0.7375 0.047/0.737 0.7835 0.024/0.867 0.0609
Leukocytes 0.101/0.471 0.4833 0.256/0.064 0.1695 0.162/0.247 0.1122
Neutrophils 0.125/0.372 0.4689 0.237/0.088 0.0969 0.183/0.190 0.0740
Lymphocytes 0.071/0.613 0.2391 0.118/0.401 0.9156 0.073/0.605 0.1955
Platelets −0.170/0.223 0.3899 0.063/0.653 0.6527 −0.350/0.806 0.9802
Creatinine −0.055/0.698 0.7700 0.105/0.459 0.5176 0.290/0.037 0.3827
Creatinine clearance 0.009/0.951 0.9380 0.096/0.496 0.7957 0.259/0.063 0.3884
SCT (R/p value) ULoR (p value) SCT (R/p value) ULoR (p value) SCT (R/p value) ULoR (p value)
Severity by grade
Anaemia 0.073/0.601 0.3811 0.141/0.315 0.4889 0.025/0.858 0.3717
Leukopenia 0.041/0.771 0.8971 −0.039/0.784 0.5143 0.061/0.663 0.7397
Neutropenia −0.007/0.960 0.9863 −0.067/0.632 0.3471 0.047/0.741 0.7066
Lymphopenia 0.071/0.613 0.4500 0.118/0.401 0.2684 0.073/0.605 0.7810
Thrombocytopenia 0.038/0.786 0.3511 −0.067/0.631 0.2847 −0.020/0.889 0.4774
Increase in serum creatinine −0.069/0.627 0.6263 0.200/0.155 0.9527 0.325/0.019 0.1462
Reduction in creatinine clearance −0.100/0.483 0.4715 0.249/0.078 0.9217 0.276/0.050 0.7730
Nausea −0.065/0.642 0.6791 −0.124/0.377 0.5203 0.009/0.949 0.7742
Vomiting −0.101/0.471 0.4140 −0.154/0.270 0.7819 −0.024/0.866 0.9087
Diarrhoea −0.195/0.161 0.1685 −0.103/0.463 0.3765 −0.044/0.754 0.6894
SCT Spearman Correlation test, R correlation coefficient, ULiR Univariate Linear Regression, ULoR Univariate Logistic Regression. For ULoR, p values were only
showed, because all values were > 0.05, odds ratio and 95% confidence intervals were not showed; anaemia, grade 0 versus grade 1 versus grades 2 + 3;
leukopenia, neutropenia and thrombocytopenia, grade 0 versus grades 1 + 2 + 3 + 4; lymphopenia, grades 0 + 1 versus grade 2 versus grades 3 + 4; increase in
serum creatinine, grade 0 versus grades 1 + 2; reduction in creatinine clearance, grade 0 versus grade 1 versus grades 2 + 3; nausea and vomiting, grade 0 versus
grade 1 versus grades 2 + 3; diarrhoea, grade 0 versus grades 1 + 2 + 3
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for more research on the predictors of cisplatin toxicity,
mainly related to other pharmacokinetic parameters and
pharmacogenetics. Regarding the pharmacokinetic par-
ameter distribution, cisplatin ADRs may be influenced
by the concentration of serum albumin and total pro-
teins, considering 90% of the cisplatin in plasma is
linked to proteins [7] and that it is common for cancer
patients to present with hypoalbuminemia; it can be as-
sumed that the amount of free cisplatin in the plasma of
these patients will be dependent on the concentration of
plasma proteins, and perhaps the ratio of plasma pro-
teins and excretion of cisplatin/ADRs may be important.
Holding et al. [21] showed that the quantity of cisplatin
bound to albumin is important for its toxicity and excre-
tion. This study did not measure albumin concentration
and total protein in the blood. Moreover, some reactions
common to cisplatin, such as neurotoxicity, hepatotox-
icity, ototoxicity and electrolyte disturbances, have not
been analysed. However, these parameters are already in-
cluded in our further studies. Furthermore, ADRs may
be related to genetic polymorphisms that do not neces-
sarily affect the detoxification of cisplatin. One must also
consider the possible errors in urine sample collection
as a limitation of this study.
Conclusion
The incidence of ADRs to cisplatin was high after the first
cycle of chemotherapy, and haematologic (lymphopenia
and anaemia) and gastrointestinal (nausea) reactions were
the most frequent. Grade 1 and 2 toxicity were prevalent
for most ADRs. The maximum excretion of cisplatin was
observed 0–12 h after chemotherapy and the amount of
cisplatin excreted could not be used to predict ADRs.
Other pharmacokinetic and genetic parameters should be
further studied to elucidate and prevent cisplatin ADRs.
Abbreviations
ADRs: Adverse drug reactions; ATP: Adenosine Triphosphate;
CTCAE: Common Terminology Criteria for Adverse Events;
DDTC: Diethyldithiocarbamate; HNSCC: Head and Neck Squamous Cell
Carcinomas; HPLC: High Performance Liquid Chromatography; KPS: Karnofsky
Performance Status; R: Correlation coefficient; SCT: Spearman Correlation test;
SI: Smoking index; ULiR: Univariate Linear Regression; ULoR: Univariate
Logistic Regression
Acknowledgments
The authors would like to thank the statistical team of School of Medical
Sciences of University of Campinas by statistical analysis support.
Funding
São Paulo Research Foundation (FAPESP) (grant numbers 2012/01807-2,
2014/18294-3 and 2014/04744-7) and Coordination for the Improvement of
Higher Level Personnel (CAPES).
Availability of data and materials
Not applicable.
Authors’ contributions
PM, CSPL and MBV were responsible for study concept and design. MBV
recruited and monitored the subjects. MBV and GBF analyzed and
interpreted the patient data regarding the ADRs. ECP performed the kinetics
of cisplatin excretion in urine analysis. MBV performed the data analysis. MBV,
GBF, JCFQ and PM participated in writing the manuscript. PGM, CSPL and
PM supervised the study. All authors read and approved the final manuscript.
Competing interests
The authors declare that there are no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The Research Ethics Committee of School of Medical Sciences of University
of Campinas approved this study and all patients signed a consent form
authorising use of their data (number 274/2011, CAAE: 0218.0.146.000-11).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1School of Medical Sciences (FCM), University of Campinas (UNICAMP),
Tessália Vieira de Camargo, 126, Cidade Universitária “Zeferino Vaz”, Zip Code
13083-887 Campinas, SP, Brazil. 2Department of Biological and Health
Science Center, Mackenzie Presbyterian University, Rua da Consolação 896,
Consolação, Zip Code 01302-907 São Paulo, SP, Brazil. 3Faculty of
Pharmaceutical Sciences (FCF), University of Campinas (UNICAMP), Cândido
Portinari, 200, Cidade Universitária “Zeferino Vaz” - Barão Geraldo, Zip Code
13083-871 Campinas, SP, Brazil.
Received: 7 February 2017 Accepted: 11 April 2017
References
1. Dobrossy L. Epidemiology of head and neck cancer: magnitude of the
problem. Cancer Metastasis Rev. 2005;24:9–17.
2. Bourhis J, Amand C, Pignon JP. Update of MACH-NC (Meta-analysis of
chemotherapy in head and neck cancer) database focused on concomitant
chemoradiotherapy. J Clin Oncol. 2004;22:5505.
3. Adelstein DJ, Li Y, Adams GL, Wagner Jr H, Kish JA, Ensley JF, et al. An
Intergroup phase III comparasion of standard radiation therapy and two
schedules of concurrent chemoradiotherapy in patients with unresectable
squamous cell head and neck cancer. J Clin Oncol. 2003;21:92–8.
4. Rosenthal DI, Ang KK. Altered radiation therapy fractionation,
chemoradiation, and patient selection for the treatment of head and neck
squamous carcinoma. Semin Radiat Oncol. 2004;14:153–66.
5. Chu E, Terry KJ, Obermiller A, Harrold LJ, Tiedemannd D, Copur MS, Chu E,
DeVita VT. Chemotherapeutic and Biologic Drugs. In: Physician’s Cancer
Chemotherapy Drug Manual 2013. Massachusetts: Jones and Bartlett
Publishers; 2013. p. 94–8.
6. Uozomi U, Litterest CL. The effect of cisplatin on renal ATPase activity in
vivo and in vitro. Cancer Chemother Pharmacol. 1985;15:93–6.
7. DeConti RC, Toftness BR, Lange RC, Creasey WA. Clinical and pharmacological
studies with cis-diamminedichloroplatinum (II). Cancer Res. 1973;33:1310–15.
8. Stewart DJ, Benjamin RS, Luna M, Feun L, Caprioli R, Seifert W, et al. Human
tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer
Chemother Pharmacol. 1982;10:51–4.
9. Nishimura T, Newkirk K, Sessions RB, Andrews PA, Trock BJ, Rasmussen AA,
et al. Immunohistochemical staining for glutathione S-transferase predicts
response to platinum-based chemotherapy in head and neck cancer. Clin
Cancer Res. 1996;2:1859–65.
10. Surowiak P, Materna V, Kaplenko I, Spaczyński M, Dietel M, Lage H, et al.
Augmented expression of metallothionein and glutathione S-transferase pi
as unfavourable prognostic factors in cisplatin-treated ovarian cancer
patients. Virchows Arch. 2005;447:626–33.
11. Jacobs C, Kalman SM, Tretton M, Weiner MW. Renal handling of cis-
diamminedichloroplatinum (II). Cancer Treat Rep. 1980;64:1223–6.
12. Lanjwani SN, Zhu R, Khuhawar MY, Ding Z. High performance liquid
chromatographic determination of platinum in blood and urine samples of
cancer patients after administration of cisplatin drug using solvent
Visacri et al. DARU Journal of Pharmaceutical Sciences  (2017) 25:12 Page 8 of 9
extraction and N, N'-bis(salicylidene)-1,2-propanediamine as complexation
reagent. J Pharm Biomed Anal. 2006;40:833–9.
13. Reed E, Ozols RF, Tarone R, Yuspa SH, Poirier MC. The measurement of
cisplatin-DNA adduct levels in testicular cancer patients. Carcinogenesis.
1988;9:1909–11.
14. Veal GJ, Dias C, Price L, Parry A, Errington J, Hale J, et al. Influence of cellular
factors and pharmacokinetics on the formation of platinum-DNA adducts in
leukocytes of children receiving cisplatin therapy. Clin Cancer Res. 2001;7:
2205–12.
15. Jindal SK, Malik SK, Dhand R, Gujral JS, Malik AK, Datta BN. Bronchogenic
carcinoma in Northern India. Thorax. 1982;37:343–7.
16. Whitcomb DC, Yadav D, Adam S, Hawes RH, Brand RE, Anderson MA, et al.
Multicenter approach to recurrent acute and chronic pancreatitis in the
United States: the North American Pancreatitis Study 2 (NAPS2).
Pancreatology. 2008;8:520–31.
17. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed.
New York: Springer; 2002.
18. U.S Department of Health and Human Services. Common Terminology
Criteria for Adverse Events (CTCAE). U.S Department of Health and Human
Services, National Institutes of Health, National Cancer Institute, Version 4.0.
2010. https://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.02_2009-09-15_
QuickReference_8.5x11.pdf. Accessed 15 May 2011.
19. Tang H, Jing J, Bo D, Xu D. Biological variations of leukocyte numerical and
morphologic parameters determined by UniCel DxH 800 hematology
analyzer. Arch Pathol Lab Med. 2012;136:1392–6.
20. Ricós C, Iglesias N, García-Lario JV, Simón M, Cava F, Hernández A, et al.
Within-subject biological variation in disease: collated data and clinical
consequences. Ann Clin Biochem. 2007;44:343–52.
21. Holding JD, Lindup WE, van Laer C, Vreeburg GC, Schilling V, Wilson JA, et
al. Phase I trial of a cisplatin-albumin complex for the treatment of cancer
of the head and neck. Br J Clin Pharmacol. 1992;33:75–81.
22. Vouillamoz-Lorenz S, Bauer J, Lejeune F, Decosterd LA. Validation of an AAS
method for the determination of platinum in biological fluids from patients
receiving the oral platinum derivative JM216. J Pharm Biomed Anal.
2001;25:465–75.
23. Bannister SJ, Sternson LA, Repta AJ. Urine analysis of platinum species
derived from cis-di-chloroammineplatinum (II) by high-performance liquid
chromatography following derivatization with sodium
diethyldithiocarbamate. J Chromatogr. 1979;173:333–42.
24. Lopez-Flores A, Jurado R, Garcia-Lopez P. A high-performance liquid
chromatographic assay for determination of cisplatin in plasma, cancer cell,
and tumor samples. J Pharmacol Toxicol Methods. 2005;52:366–72.
25. Qiu MZ, Xu RH, Ruan DY, Li ZH, Luo HY, Teng KY, et al. Incidence of anemia,
leukocytosis, and thrombocytosis in patients with solid tumors in China.
Tumour Biol. 2010;31:633–41.
26. de Castro Jr G, Snitcovsky IM, Gebrim EM, Leitão GM, Nadalin W, Ferraz AR,
et al. High-dose cisplatin concurrent to conventionally delivered
radiotherapy is associated with unacceptable toxicity in unresectable, non-
metastatic stage IV head and neck squamous cell carcinoma. Eur Arch
Otorhinolaryngol. 2007;264:1475–82.
27. Trellakis S, Bruderek K, Dumitru CA, Gholaman H, Gu X, Bankfalvi A, et al.
Polymorphonuclear granulocytes in human head and neck cancer:
enhanced inflammatory activity, modulation by cancer cells and expansion
in advanced disease. Int J Cancer. 2011;129:2183–93.
28. Son JY, Shin JW, Wang JH, Park HJ, Kim HG, Raghavendran HR, et al.
Chemotherapy-induced myelotoxicity and incidence of lung metastasis in
an animal model. Hum Exp Toxicol. 2011;30:649–55.
29. Arunkumar P, Viswanatha G, Radheshyam N, Mukund H, Belliyappa M.
Science behind cisplatin-induced nephrotoxicity in humans: A clinical study.
Asian Pac J Trop Biomed. 2012;2:640–4.
30. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity
associated with platinating agents. Cancer Treat Rev. 2007;33:9–23.
31. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug
Saf. 1995;13:228–44.
32. Surendiran A, Balamurugan N, Gunaseelan K, Akhtar S, Reddy KS, Adithan C.
Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a
tertiary care hospital in India: An evaluative study. Indian J Pharmacol. 2010;42:40–3.
33. Hanai N, Suzuki A, Ozawa T, Hirakawa H, Hasegawa Y. Postoperative
chemoradiotherapy with weekly cisplatin for patients at high-risk for
recurrence of head and neck squamous cell carcinoma-A phase I/II study.
Gan To Kagaku Ryoho. 2012;39:1495–500.
34. Kris MG, Gralla RJ, Clark RA, Tyson LB, O'Connell JP, Wertheim MS, et al.
Incidence, course, and severity of delayed nausea and vomiting following
the administration of high-dose cisplatin. J Clin Oncol. 1985;3:1379–84.
35. Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H. Chemotherapy-induced
nausea and vomiting: incidence and impact on patient quality of life at
community oncology settings. Support Care Cancer. 2007;15:497–503.
36. Litterest CL, Gram TE, Dedrick RL, Leroy AF, Guarino AM. Distribution and
disposition of platinum following intravenous administration of cis-
diamminedichloroplatinum (ll) (NSC-119875) to dogs. Cancer Res. 1976;36:
2340–4.
37. Litterest CL, Torres IJ, Guarino AM. Plasma levels and organ distribution of
Pt in the rat, dog and dogfish shark following single intravenous
administration of cis-dichlorodiammineplatinum (II). J Clin Hematol Oncol.
1977;7:169.
38. Gullo JJ, Litterst CL, Maguire PJ, Sikic BI, Hoth DF, Woolley PV.
Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II)
administered as a one hour or as a twenty hour infusion. Cancer
Chemother Pharmacol. 1980;5:21–6.
39. Siddik ZH, Jones M, Boxall FE, Harrap KR. Comparative distribution and
excretion of carboplatin and cisplatin in mice. Cancer Chemother
Pharmacol. 1988;21:19–24.
40. Andersson A, Fagerberg J, Lewensohn R, Ehrsson H. Pharmacokinetics of
cisplatin and its monohydrated complex in humans. J Pharm Sci.
1996;85:824–7.
41. Nagai N, Okuda R, Kinoshita M, Ogata H. Decomposition kinetics of cisplatin
in human biological fluids. J Pharm Pharmacol. 1996;48:918–24.
42. de Jonge MJ, Verweij J, de Bruijn P, Brouwer E, Mathijssen RH, van Alphen
RJ, et al. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a
dose-escalating study of irinotecan and cisplatin. J Clin Oncol.
2000;18:195–203.
43. Cameron JR, Skofronick JG, Grant RM. Physics of the body. Madison: Medical
Physics Publishing; 1999.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Visacri et al. DARU Journal of Pharmaceutical Sciences  (2017) 25:12 Page 9 of 9
